Market Spotlight: Idiopathic pulmonary fibrosis (IPF)
Market Spotlight: Idiopathic pulmonary fibrosis (IPF)
$1,318.00
This Market Spotlight report covers the Idiopathic pulmonary fibrosis (IPF) market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Idiopathic Pulmonary Fibrosis (IPF) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, 10-year disease incidence and prevalence forecasts, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2019, there were 187,040 incident cases and 714,260 prevalent cases of idiopathic pulmonary fibrosis (IPF) in adults aged 20 years and older worldwide, and forecasts those numbers to increase to 209,960 incident cases and 798,760 prevalent cases by 2028.
- Roche’s Esbriet and Boehringer Ingelheim’s Ofev are the only approved drugs for IPF. These drugs are administered via the oral route.
- The largest proportion of industry-sponsored drugs in active clinical development for IPF are in Phase II, with two drugs in Phase III.
- Therapies in development for IPF focus on a wide variety of targets. The majority of pipeline drugs in development are administered via the oral route.
- High-impact upcoming events in the IPF space comprise topline Phase IIa trial results for PLN-74809, topline Phase IIb trial results for GB0139, topline Phase II trial results for GLPG1205, and topline Phase III trial results for GLPG1690 and pamrevlumab.
- The overall likelihood of approval of a Phase I respiratory-other asset is 6.4%, and the average probability a drug advances from Phase III is 41.7%. Drugs, on average, take 12.4 years from Phase I to approval, compared to 9.4 years in the overall respiratory space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for IPF have been in the early and midphases of development, with 66% of trials in Phase I–II, and 34% in Phase III–IV.
- The US has a substantial lead in the number of IPF clinical trials globally. The UK leads the major European markets, while Israel has the top spot in Asia.
- Clinical trial activity in the IPF space is dominated by completed trials. Roche has the highest number of completed clinical trials for IPF, with 19 trials.
- Roche leads the industry sponsors with the highest overall number of clinical trials for IPF, followed by Boehringer Ingelheim.
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Disease definition
7 Patient segmentation
7 Symptoms
7 Risk factors
8 Diagnosis
9 TREATMENT
9 Pharmacologic treatment
9 Non-pharmacologic treatments
11 EPIDEMIOLOGY
16 MARKETED DRUGS
18 PIPELINE DRUGS
25 RECENT EVENTS AND ANALYST OPINION
25 GLPG1690 for IPF (July 14, 2019)
27 KEY UPCOMING EVENTS
28 PROBABILITY OF SUCCESS
29 LICENSING AND ASSET ACQUISITION DEALS
29 Reborn Redx Inks Global Licensing Deal With AstraZeneca
29 Galapagos Seeks IPF Discovery Leads From E-Therapeutics
29 Roche Paying $390m Up Front For Fibrosis-Fighting Promedior
30 REVENUE OPPORTUNITY
31 CLINICAL TRIAL LANDSCAPE
32 Sponsors by status
33 Sponsors by phase
35 BIBLIOGRAPHY
36 Prescription information
37 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in incident cases of IPF, 2019–28
15 Figure 2: Trends in prevalent cases of IPF, 2019–28
18 Figure 3: Overview of pipeline drugs for IPF in the US
18 Figure 4: Pipeline drugs for IPF, by company
19 Figure 5: Pipeline drugs for IPF, by drug type
19 Figure 6: Pipeline drugs for IPF, by classification
27 Figure 7: Key upcoming events in IPF
28 Figure 8: Probability of success in the IPF pipeline
31 Figure 9: Clinical trials in IPF
31 Figure 10: Top 10 drugs for clinical trials in IPF
32 Figure 11: Top 10 companies for clinical trials in IPF
32 Figure 12: Trial locations in IPF
33 Figure 13: IPF trials status
34 Figure 14: IPF trials sponsors, by phase
LIST OF TABLES
12 Table 1: Incident cases of IPF, 2019–28
14 Table 2: Prevalent cases of IPF, 2019–28
17 Table 3: Marketed drugs for IPF
20 Table 4: Pipeline drugs for IPF in the US
25 Table 5: GLPG1690 for IPF (July 14, 2019)
30 Table 6: Historical global sales, by drug ($m), 2015–19
30 Table 7: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Bipolar Disorder Disease Coverage 
Sign up to the